Financials SMAIO

Equities

ALSMA

FR0014005I80

Pharmaceuticals

Market Closed - Euronext Paris 10:42:31 2024-05-17 am EDT 5-day change 1st Jan Change
3.44 EUR -0.29% Intraday chart for SMAIO -1.71% +11.69%

Valuation

Fiscal Period: December 2022 2023 2024 2025
Capitalization 1 16.99 17.99 17.99 -
Enterprise Value (EV) 1 11.95 16.1 17.59 17.99
P/E ratio - -12.7 x -8.82 x 34.4 x
Yield - - - -
Capitalization / Revenue 7.08 x 2.99 x 3.33 x 1.75 x
EV / Revenue 4.98 x 2.99 x 3.26 x 1.75 x
EV / EBITDA -4.7 x -49 x -12.6 x 15 x
EV / FCF 2.34 x -8.64 x -5.17 x -10.6 x
FCF Yield 42.7% -11.6% -19.3% -9.45%
Price to Book - - - -
Nbr of stocks (in thousands) 5,229 5,229 5,229 -
Reference price 2 3.250 3.440 3.440 3.440
Announcement Date 4/11/23 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 2.1 2.4 5.383 5.4 10.3
EBITDA 1 - -2.544 -0.3 -1.4 1.2
EBIT 1 - -4 -1.7 -2.4 0.2
Operating Margin - -166.67% -30.91% -44.44% 1.94%
Earnings before Tax (EBT) - - - - -
Net income 1 -3.1 2.846 -1.4 -2 0.5
Net margin -147.62% 118.57% -25.45% -37.04% 4.85%
EPS 2 - - -0.2700 -0.3900 0.1000
Free Cash Flow 1 - 5.106 -1.7 -3.4 -1.7
FCF margin - 212.73% -30.91% -62.96% -16.5%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - 179.42% - - -
Dividend per Share - - - - -
Announcement Date 4/29/22 4/11/23 - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt 1 - - - - -
Net Cash position 1 - 5.04 3.3 0.4 -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - 5.11 -1.7 -3.4 -1.7
ROE (net income / shareholders' equity) - 29.2% - - 7.2%
ROA (Net income/ Total Assets) - - - - 5.5%
Assets 1 - - - - 9.091
Book Value Per Share - - - - -
Cash Flow per Share - - - - -
Capex 1 - 0.83 1 1.5 1.5
Capex / Sales - 34.59% 18.18% 27.78% 14.56%
Announcement Date 4/29/22 4/11/23 - - -
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.44 EUR
Average target price
5.8 EUR
Spread / Average Target
+68.60%
Consensus

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW